-
Dec 5, 2024 | 
cfp.ca | Anna Wilkinson
I thank Dr Anne Katz for her comments1 regarding the inclusion of sexuality and sexual function in the cancer survivorship road map.2 Although sexual health was indeed mentioned in the survivorship road map, Dr Katz is correct this topic merits further coverage. The writing of Oncology Briefs requires a fine balance between distillation of key complex cancer topics into 2 or 3 readable pages, while simultaneously ensuring thorough evidence-based coverage.
-
Aug 9, 2024 | 
cfp.ca | Anna Wilkinson
Dans l’ensemble, l’incidence et la prévalence du cancer ont continué de grimper au cours des 3 dernières décennies et, en 2018, plus de 1,5 million de Canadiens vivaient avec le cancer ou y avaient survécu1. Les personnes qui ont terminé un traitement actif du cancer ont besoin d’un suivi continu ou de soins de survivance.
-
Aug 9, 2024 | 
cfp.ca | Anna Wilkinson
The overall incidence and prevalence of cancer have continued to climb over the past 3 decades, with more than 1.5 million Canadians living with or beyond cancer as of 2018.1 Individuals who completed active cancer treatment require ongoing follow-up or survivorship care.
-
Jun 28, 2024 | 
thetyee.ca | Anna Wilkinson
The United States Preventive Services Task Force, the Canadian Cancer Society and several Canadian provinces now endorse breast cancer screening for women aged 40 to 49, but the new guidelines from the Canadian Task Force on Preventive Health Care do not. Announcements, Events & more from Tyee and select partners ‘We’re Going to Work Together.
-
Jun 5, 2024 | 
winnipegfreepress.com | Anna Wilkinson |GP Oncologist |l’Université d’Ottawa |Jean Seely |Moira Katherine Rushton
This article was originally published on The Conversation, an independent and nonprofit source of news, analysis and commentary from academic experts. Disclosure information is available on the original site. ___Authors: Anna N.
-
May 14, 2024 | 
cfp.ca | Anna Wilkinson
In my capacity as past Chair of the Cancer Care Member Interest Group of the College of Family Physicians of Canada and regular contributor to and coordinator of the Oncology Briefs series in Canadian Family Physician, I wish to express my profound concern that Canadian Family Physician would publish an article with such blatant misinformation as was found in “Debunking myths about screening.
-
Nov 14, 2023 | 
cfp.ca | Anna Wilkinson
A deeper understanding of the importance of breast density as a breast cancer risk factor has prompted a number of provincial and territorial screening programs to inform women of their breast density test results directly. Seven Canadian provinces inform all women of their breast density. Saskatchewan and Newfoundland and Labrador are committed to implementation of density notification.
-
Aug 26, 2023 | 
mdpi.com | Anna Wilkinson |Jean Seely |Moira Katherine Rushton |Phillip Williams
1. IntroductionApproximately one in every eight women will be diagnosed with breast cancer (BC) over their lifetime, with an estimated 28,600 new cases of BC in Canada in 2022 [1,2]. BC treatment is rapidly evolving, with ongoing advances in genomic testing, radiation therapy, surgery and systemic therapy. BC molecular subtype, based on hormone receptor (HR) and HER2/neu (HER2) status, is increasingly driving specialised therapy choices and informing improved subtype-specific survival [3].
-
Aug 7, 2023 | 
lexblog.com | William Chalmers |Christopher A. Guerreiro |Anna Wilkinson |Kristin Wall
On August 7, 2023, the Canadian Intellectual Property Office (CIPO) launched a consultation on proposed features of regulations on patent term adjustment (PTA) in Canada (the Consultation). The PTA system is intended to compensate patentees for “unreasonable delays” by CIPO in issuing a patent. The Consultation seeks feedback on proposals that would impact the length of the PTA term, in order to inform the development of draft amendments to the Patent Rules.
-
Jul 14, 2023 | 
cfp.ca | Anna Wilkinson
Research ArticleOncology Briefs Canadian Family Physician 69 (7) 473-476; DOI: https://doi.org/10.46747/cfp.6907473 The first question a patient often asks their FP after receiving a diagnosis of breast cancer (BC) is “What will my treatment be?” This article will help FPs answer this complex question by reviewing multimodal therapy for BC, which is contingent on molecular subtype and stage (Figure 1).1 Pathology Initial pathology reports for BC will have both pathologic and...
